Teva Pharmaceuticals, the makers of the transdermal patch Zecuity (Sumatriptan Iontophoretic Transdermal System ) has temporarily suspended the sales, marketing and distribution of this medication. Teva has done a voluntary recall of this medication and is working with the FDA to examine all reported adverse skin reactions related to the medication. The Transdermal patch was prescribed for acute migraine headaches in adults.The patch is designed to release medication into the patients system, through a battery powered patch that is worn around the upper arm or thigh. Since the patch went on the Market in September of 2015 there have been numerous reports of adverse skin reactions associate with usage. Patients have reported scarring, pain, itching, burning, blisters, welts, cracked skin and skin discoloration. Most adverse reactions subside once the patch is removed within hours or weeks, but there have been reports of unresolved skin reactions such as discoloration several months after the patches have been removed. Teva has recalled the product from all pharmacies and have alerted health care professionals to stop prescribing it . Teva has asked all health Care Professionals to notify all patients currently on this medication to discontinue the use of Zecuity. Doctors are asked to evaluated all patients with site reactions. Patients are requested to call Migraine Support Solutions 1-855-8489 for information and safe disposal of unused patches. Teva also urges anyone that had had an adverse reaction to report it by calling 1-800-896-5855, you can also report it online to the FDA by clicking here . If you have had an adverse reaction from wearing a transdermal Zecuity patch Please Contact Us and provide any details along with contact information. If you prefer to leave a voicemail you can call 1.858.236.9020. GetClassActionMoney.com can then forward these requests to our network of attorneys that may contact you if a Class Action Lawsuit is to be pursued. In addition make sure you Subscribe to our mailing list to receive important updates regarding class action news and open cases.